FMP
NeuroSense Therapeutics Ltd.
NRSNW
NASDAQ
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline product candidates include StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
0.12 USD
-0.1396 (-115.95%)
Valuation Date:
Nov 13, 2024 4:00 PM
Share Price on Valuation Date
$0.12
Stock Beta
1.565
Shares Outstanding
210429177